3 reports of this reaction
11.1% of all STRYCHNOS IGNATII SEED reports
#1 most reported adverse reaction
ALOPECIA is the #1 most commonly reported adverse reaction for STRYCHNOS IGNATII SEED, manufactured by Aurobindo Pharma Limited. There are 3 FDA adverse event reports linking STRYCHNOS IGNATII SEED to ALOPECIA. This represents approximately 11.1% of all 27 adverse event reports for this drug.
Patients taking STRYCHNOS IGNATII SEED who experience alopecia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ALOPECIA is a frequently reported adverse event for STRYCHNOS IGNATII SEED, accounting for a significant proportion of all reports.
In addition to alopecia, the following adverse reactions have been reported for STRYCHNOS IGNATII SEED:
The following drugs have also been linked to alopecia in FDA adverse event reports:
ALOPECIA has been reported as an adverse event in 3 FDA reports for STRYCHNOS IGNATII SEED. This does not prove causation, but indicates an association observed in post-market surveillance data.
ALOPECIA accounts for approximately 11.1% of all adverse event reports for STRYCHNOS IGNATII SEED, making it one of the most commonly reported side effect.
If you experience alopecia while taking STRYCHNOS IGNATII SEED, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.